Molecular Landscape of Lung Cancer: Insights Into Therapeutic Targets and Clinical Outcomes

The document provides an in-depth analysis of the molecular landscape of lung cancer (LC), emphasizing the challenges posed by its heterogeneity and the advancements in therapeutic targets and clinical outcomes. LC is a major cause of cancer-related deaths, with a low 5-year survival rate of 18.6%. The review highlights the complexity of LC due to diverse genetic mutations, such as EGFR, ALK, and KRAS, which complicate drug development. Despite these challenges, progress has been made in personalized therapy and identifying new drug targets, including protein kinases and immune checkpoint therapies. Key pathways like EGFR, ALK, and PI3K/AKT/mTOR are discussed, with targeted therapies showing efficacy in treating non-small cell lung cancer (NSCLC). The document underscores the importance of targeting cellular processes and signaling pathways to develop novel treatments, while also noting the shift from traditional chemotherapies to targeted therapies and immunotherapies. Future research should focus on novel biomarkers and combination therapies to enhance personalized treatment strategies.